Drug Trial Radar · NCT00556673
Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma
Last checked: Nov 19, 2026Latest source record: Apr 22, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Oct 2007
Primary completion
Apr 2008
Study completion Apr 2008
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Nov 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the bronchodilatory efficacy of indacaterol maleate 500 μg/mometasone furoate 400 μg via the Twisthaler® device in adult patients with persistent asthma.
Conditions
- Asthma
Interventions
indacaterol maleate/mometasone furoateDrug
Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.
placebo to indacaterol maleate/mometasone furoateDrug
Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
fluticasone proprionate / salmeterol xinafoateDrug
Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)Time frame: Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16).
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigator Site
Poitiers, France
Novartis Investigator Site
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.